S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
How major US stock indexes fared Friday, 4/19/2024
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Marker Therapeutics (MRKR) Competitors

$4.14
+0.04 (+0.98%)
(As of 05:21 PM ET)

MRKR vs. ELDN, VIRX, CASI, VYNE, THTX, XLO, NBRV, CARA, BCTX, and UNCY

Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Eledon Pharmaceuticals (ELDN), Viracta Therapeutics (VIRX), CASI Pharmaceuticals (CASI), VYNE Therapeutics (VYNE), Theratechnologies (THTX), Xilio Therapeutics (XLO), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), BriaCell Therapeutics (BCTX), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.

Marker Therapeutics vs.

Marker Therapeutics (NASDAQ:MRKR) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Marker Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Marker Therapeutics received 46 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 70.59% of users gave Eledon Pharmaceuticals an outperform vote while only 63.06% of users gave Marker Therapeutics an outperform vote.

CompanyUnderperformOutperform
Marker TherapeuticsOutperform Votes
70
63.06%
Underperform Votes
41
36.94%
Eledon PharmaceuticalsOutperform Votes
24
70.59%
Underperform Votes
10
29.41%

Eledon Pharmaceuticals has a consensus price target of $10.67, suggesting a potential upside of 473.48%. Given Eledon Pharmaceuticals' higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Marker Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Eledon Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Marker Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.31M11.13-$8.24MN/AN/A
Eledon PharmaceuticalsN/AN/A-$40.33M-$1.79-1.04

Eledon Pharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -142.62%. Marker Therapeutics' return on equity of -39.89% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker Therapeutics-142.62% -39.89% -25.45%
Eledon Pharmaceuticals N/A -46.15%-43.10%

In the previous week, Marker Therapeutics' average media sentiment score of 0.00 equaled Eledon Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Marker Therapeutics Neutral
Eledon Pharmaceuticals Neutral

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 24.1% of Marker Therapeutics shares are owned by insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Marker Therapeutics beats Eledon Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

MetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$36.85M$6.11B$4.78B$7.31B
Dividend YieldN/A3.11%2.93%4.01%
P/E RatioN/A11.06222.7416.38
Price / Sales11.13282.522,474.4389.25
Price / CashN/A29.8946.9434.82
Price / Book2.625.434.554.14
Net Income-$8.24M$133.78M$103.79M$214.16M
7 Day Performance-3.94%-6.67%-4.37%-3.50%
1 Month Performance-5.91%-8.56%-5.96%-3.95%
1 Year Performance324.57%-6.71%6.71%3.40%

Marker Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
2.2548 of 5 stars
$1.66
-4.0%
$10.67
+542.6%
-18.4%$41.19MN/A-0.9317Gap Up
VIRX
Viracta Therapeutics
1.19 of 5 stars
$1.06
-0.9%
$5.00
+371.7%
-29.5%$41.63MN/A-0.8040Analyst Report
News Coverage
Gap Down
CASI
CASI Pharmaceuticals
3.7206 of 5 stars
$3.13
+0.6%
$12.00
+283.4%
-30.2%$41.95M$33.88M-1.55224Gap Down
VYNE
VYNE Therapeutics
2.7058 of 5 stars
$2.76
+0.7%
$7.38
+167.2%
-26.5%$38.92M$420,000.00-0.3910Positive News
THTX
Theratechnologies
0 of 5 stars
$1.54
+6.2%
N/A-66.3%$37.27M$81.76M-1.62103Gap Up
XLO
Xilio Therapeutics
2.6778 of 5 stars
$1.31
-10.9%
N/A-59.6%$45.16MN/A-0.4781Positive News
Gap Down
NBRV
Nabriva Therapeutics
0 of 5 stars
N/AN/AN/A$45.46M$35.59M-0.0739Analyst Report
CARA
Cara Therapeutics
3.931 of 5 stars
$0.83
+1.2%
$9.75
+1,071.9%
-83.8%$45.48M$20.97M-0.3855Gap Up
BCTX
BriaCell Therapeutics
1.5407 of 5 stars
$2.85
-2.7%
$18.00
+531.6%
-70.4%$45.55MN/A-1.7016Positive News
UNCY
Unicycive Therapeutics
2.7845 of 5 stars
$1.32
-4.3%
$5.30
+301.5%
-36.6%$45.88M$680,000.00-0.8512

Related Companies and Tools

This page (NASDAQ:MRKR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners